Lyka Labs Ltd is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products, including injectables, topical formulations, and other specialty medicines. Lyka Labs Share Price on NSE as of 9 January 2025 is 148.61 INR. Here will provide you more details on Lyka Labs Share Price Target 2025, 2026 to 2030.
Lyka Labs Ltd: Market Overview
- Open: ₹157.88
- High: ₹158.23
- Low: ₹146.50
- Previous Close: ₹157.71
- Volume: 110,556
- Value (Lacs): ₹163.49
- VWAP: ₹150.91
- UC Limit: ₹189.25
- LC Limit: ₹126.16
- 52 Week High: ₹176.59
- 52 Week Low: ₹97.90
- Mkt Cap (Rs. Cr.): ₹489
- Face Value: ₹10
Lyka Labs Share Price Chart
Lyka Labs Share Price Target Tomorrow 2025 To 2030
| Lyka Labs Share Price Target Years | Share Price Target |
| 2025 | ₹180 |
| 2026 | ₹205 |
| 2027 | ₹230 |
| 2028 | ₹270 |
| 2029 | ₹300 |
| 2030 | ₹330 |
Lyka Labs Share Price Target 2025
Lyka Labs share price target 2025 Expected target could be ₹180. Here are 4 Key Factors Affecting Growth for “Lyka Labs Share Price Target 2025”:
- New Product Launches: The introduction of innovative pharmaceutical products and formulations, especially in niche therapeutic areas, could drive revenue growth and boost investor confidence.
- Regulatory Approvals: Obtaining approvals for products in highly regulated markets like the US and Europe can open new growth opportunities and enhance market reach.
- Expansion in Export Markets: Increasing exports to semi-regulated and emerging markets could contribute significantly to revenue growth, given the rising demand for quality generics and specialty medicines.
-
Strategic Collaborations: Partnerships with global pharmaceutical companies for manufacturing or marketing could enhance operational efficiency and increase Lyka Labs’ visibility in international markets.
Lyka Labs Share Price Target 2030
Lyka Labs share price target 2030 Expected target could be ₹330. Here are 4 Risks and Challenges for “Lyka Labs Share Price Target 2030”:
- Regulatory Hurdles: Stringent compliance requirements in international markets, such as the US FDA and EU regulations, could lead to delays or restrictions in product approvals, impacting revenue.
- Competitive Pressure: Increased competition from domestic and international pharmaceutical companies could lead to pricing pressure and reduced market share, especially in generic medicines.
- R&D and Innovation Risks: Failure to develop innovative products or delays in launching new drugs could hinder growth and affect the company’s long-term profitability.
-
Macroeconomic and Currency Risks: Fluctuations in foreign exchange rates and adverse economic conditions in key export markets could negatively affect earnings and financial stability.
Lyka Labs Ltd Shareholding Pattern
- Promoters: 58.10%
- Retail and Others: 41.08%
- DII: 0.66%
- FII: 0.15%
- Mutual Funds: 0.01%
Lyka Labs Ltd Financials
| (INR) | 2024 | Y/Y change |
| Revenue | 1.06B | 18.75% |
| Operating expense | 567.24M | 19.65% |
| Net income | -24.89M | 81.16% |
| Net profit margin | -2.34 | 84.17% |
| Earnings per share | — | — |
| EBITDA | 135.72M | -19.67% |
| Effective tax rate | -180.61% | — |
Read Also:- SIL Investments Share Price Target Tomorrow 2025 To 2030 – Stock Market Update
